CL2008003938A1 - Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00). - Google Patents

Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).

Info

Publication number
CL2008003938A1
CL2008003938A1 CL2008003938A CL2008003938A CL2008003938A1 CL 2008003938 A1 CL2008003938 A1 CL 2008003938A1 CL 2008003938 A CL2008003938 A CL 2008003938A CL 2008003938 A CL2008003938 A CL 2008003938A CL 2008003938 A1 CL2008003938 A1 CL 2008003938A1
Authority
CL
Chile
Prior art keywords
escitalopram
prepare
post
treatment
pharmaceutically acceptable
Prior art date
Application number
CL2008003938A
Other languages
English (en)
Inventor
Connie Sanchez
Sandra Hogg
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003938(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2008003938A1 publication Critical patent/CL2008003938A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo que sirve para preparar un medicamento útil en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
CL2008003938A 1999-07-08 2008-12-30 Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00). CL2008003938A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08

Publications (1)

Publication Number Publication Date
CL2008003938A1 true CL2008003938A1 (es) 2009-05-22

Family

ID=8099796

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2008003939A CL2008003939A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
CL2008003938A CL2008003938A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
CL2008003941A CL2008003941A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2008003939A CL2008003939A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2008003941A CL2008003941A1 (es) 1999-07-08 2008-12-30 Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.

Country Status (38)

Country Link
US (6) US7271194B2 (es)
EP (4) EP1200081B1 (es)
JP (1) JP4773011B2 (es)
KR (1) KR100604176B1 (es)
CN (1) CN1198610C (es)
AR (1) AR021155A1 (es)
AT (1) ATE339955T1 (es)
AU (6) AU782514B2 (es)
BG (4) BG106279A (es)
BR (1) BR0011578A (es)
CA (4) CA2687394A1 (es)
CL (3) CL2008003939A1 (es)
CO (1) CO5190674A1 (es)
CY (1) CY1105806T1 (es)
CZ (1) CZ200270A3 (es)
DE (1) DE60030861T2 (es)
DK (1) DK1200081T3 (es)
EA (1) EA006555B1 (es)
ES (1) ES2272298T3 (es)
HK (1) HK1048069B (es)
HR (1) HRP20010820A2 (es)
HU (1) HUP0201791A3 (es)
IL (5) IL146131A0 (es)
IS (1) IS6137A (es)
ME (2) ME00032B (es)
MX (1) MXPA01011626A (es)
MY (1) MY143278A (es)
NO (4) NO329021B1 (es)
PL (1) PL352030A1 (es)
PT (1) PT1200081E (es)
SI (1) SI1200081T1 (es)
SK (1) SK82002A3 (es)
TR (4) TR200200014T2 (es)
TW (1) TWI232101B (es)
UA (1) UA77645C2 (es)
WO (1) WO2001003694A1 (es)
YU (1) YU78701A (es)
ZA (1) ZA200108856B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
JP2004504393A (ja) 2000-07-21 2004-02-12 ハー・ルンドベック・アクチエゼルスカベット 新規化合物及びそのグリシントランスポート阻害剤としての使用方法
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
IL159326A0 (en) 2001-07-31 2004-06-01 Lundbeck & Co As H Crystalline composition containing escitalopram
AU2003237524A1 (en) * 2002-07-08 2004-01-23 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
MXPA05005772A (es) * 2002-12-23 2005-08-16 Lundbeck & Co As H Bromhidrato de escitalopram y un metodo para su preparacion.
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
EP1708790B1 (en) * 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EA200801081A1 (ru) 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (es) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4439545A (en) 1981-11-19 1984-03-27 Societe D "Expansion Scientifique "Expansia" Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
WO1993009769A1 (en) 1991-11-15 1993-05-27 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
DK0759299T3 (da) 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
JP3813820B2 (ja) * 1997-11-11 2006-08-23 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
PT957099E (pt) * 1998-04-15 2003-02-28 Pfizer Prod Inc Carboxamidas heterociclicas
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
AU771252B2 (en) 1998-07-13 2004-03-18 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression and other disorders
JP2002520353A (ja) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
WO2000023431A1 (en) * 1998-10-20 2000-04-27 H. Lundbeck A/S Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
CN1142926C (zh) * 1999-04-14 2004-03-24 H·隆德贝克有限公司 制备西酞普兰的方法
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
JP2003531169A (ja) 2000-04-24 2003-10-21 アリックス セラピューティクス うつ病治療のための材料と方法
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram

Also Published As

Publication number Publication date
NO20100335L (no) 2002-01-07
AU2005202685B2 (en) 2009-01-15
CL2008003941A1 (es) 2009-05-22
US7265151B2 (en) 2007-09-04
HUP0201791A2 (en) 2002-10-28
US20020086899A1 (en) 2002-07-04
PL352030A1 (en) 2003-07-28
HRP20010820A2 (en) 2003-08-31
AU2005202686B2 (en) 2009-01-15
AU2005202686A1 (en) 2005-07-14
ES2272298T3 (es) 2007-05-01
CO5190674A1 (es) 2002-08-29
AU2008264182A1 (en) 2009-01-29
EP1440691A2 (en) 2004-07-28
KR100604176B1 (ko) 2006-07-25
BG110468A (en) 2010-01-29
NO329021B1 (no) 2010-07-26
JP4773011B2 (ja) 2011-09-14
TR200402275T2 (tr) 2005-03-21
IS6137A (is) 2001-10-30
ZA200108856B (en) 2002-12-24
DE60030861D1 (de) 2006-11-02
BG110467A (en) 2010-01-29
EP1200081B1 (en) 2006-09-20
US20040029958A1 (en) 2004-02-12
CN1360501A (zh) 2002-07-24
WO2001003694A1 (en) 2001-01-18
TR200402277T2 (tr) 2005-01-24
SK82002A3 (en) 2002-07-02
AU782514B2 (en) 2005-08-04
US20040029957A1 (en) 2004-02-12
CZ200270A3 (cs) 2002-04-17
IL170192A (en) 2010-04-29
CA2687392A1 (en) 2001-01-18
US20040029956A1 (en) 2004-02-12
AU2005202684A1 (en) 2005-07-14
EP1440689A3 (en) 2004-08-25
CA2373757C (en) 2010-01-05
KR20020015346A (ko) 2002-02-27
PT1200081E (pt) 2007-01-31
AU2005202685A1 (en) 2005-07-14
BR0011578A (pt) 2002-03-26
CL2008003939A1 (es) 2009-06-05
TWI232101B (en) 2005-05-11
NO20020062D0 (no) 2002-01-07
MEP2508A (xx) 2010-02-10
HK1048069B (zh) 2005-12-16
HUP0201791A3 (en) 2005-02-28
AU2005202684B2 (en) 2009-01-15
AR021155A1 (es) 2002-06-12
ATE339955T1 (de) 2006-10-15
EP1440691A3 (en) 2004-08-25
MY143278A (en) 2011-04-15
DE60030861T2 (de) 2007-05-03
TR200402276T2 (tr) 2005-01-24
AU5806100A (en) 2001-01-30
CN1198610C (zh) 2005-04-27
US6960613B2 (en) 2005-11-01
NO20100334L (no) 2002-01-07
US7271194B2 (en) 2007-09-18
US20070276035A1 (en) 2007-11-29
IL146131A0 (en) 2002-07-25
DK1200081T3 (da) 2006-12-27
YU78701A (sh) 2004-03-12
TR200200014T2 (tr) 2002-05-21
HK1048069A1 (en) 2003-03-21
US20050101665A1 (en) 2005-05-12
EP1440690A3 (en) 2004-08-18
EP1440689A2 (en) 2004-07-28
EP1440690A2 (en) 2004-07-28
EP1200081A1 (en) 2002-05-02
IL170194A (en) 2010-05-31
IL170193A (en) 2010-04-29
EA200200137A1 (ru) 2002-06-27
CA2687396A1 (en) 2001-01-18
CA2373757A1 (en) 2001-01-18
CA2687394A1 (en) 2001-01-18
IL146131A (en) 2007-02-11
ME00032B (me) 2010-02-10
UA77645C2 (en) 2007-01-15
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
CY1105806T1 (el) 2011-02-02
AU2008264188A1 (en) 2009-05-07
MXPA01011626A (es) 2002-06-04
BG110466A (en) 2010-01-29
NO20100333L (no) 2002-01-07
JP2003504332A (ja) 2003-02-04
BG106279A (bg) 2002-08-30
EA006555B1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
CL2004000675A1 (es) Uso de una combinacion de androgeno de origen biogenico o sintetico y un estrogeno de origen biogenico o sintetico para preparar un medicamento util en el tratamiento del hipogonadismo y enfermedades hipofisis o glandula pituitaria en hombres, para e
ES2159591T3 (es) Composicion de liberacion controlada.
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
PA8514401A1 (es) Nuevos derivados de piperazina
BR0009480A (pt) Soluções de poliuretano com unidades de estrutura de alcoxissilano
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
PE20010710A1 (es) Tratamiento de desordenes del sueno por medio del uso de desloratadina
DE69932510D1 (de) Vaskularisierungsinhibitoren
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
AR008908A1 (es) Uso de loratadina y un descongestivo para preparar un medicamento para mejorar la funcion pulmonar de un paciente que padece asma
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
CO5200850A1 (es) Composicion farmaceutica para profilaxis y tratamiento de sintomas asociados con la gripa, influenza y enfermedades similares y procedimiento para su aplicacion
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
DE59914183D1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
SE0000303D0 (sv) Novel compounds
AR014082A1 (es) Concentrado oral de sertralina